<SEC-DOCUMENT>0001104659-22-008997.txt : 20220128
<SEC-HEADER>0001104659-22-008997.hdr.sgml : 20220128
<ACCEPTANCE-DATETIME>20220128161050
ACCESSION NUMBER:		0001104659-22-008997
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20211115
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20220128
DATE AS OF CHANGE:		20220128

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BRAINSTORM CELL THERAPEUTICS INC.
		CENTRAL INDEX KEY:			0001137883
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				207273918
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36641
		FILM NUMBER:		22568886

	BUSINESS ADDRESS:	
		STREET 1:		1325 AVENUE OF AMERICAS
		STREET 2:		28TH FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10019
		BUSINESS PHONE:		201-488-0460

	MAIL ADDRESS:	
		STREET 1:		1325 AVENUE OF AMERICAS
		STREET 2:		28TH FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10019

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BRAINSTORM CELL THERAPEUTICS INC
		DATE OF NAME CHANGE:	20041122

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	GOLDEN HAND RESOURCES INC
		DATE OF NAME CHANGE:	20030827

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	WIZBANG TECHNOLOGIES INC
		DATE OF NAME CHANGE:	20010409
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>tm223729d1_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:us-roles="http://fasb.org/us-roles/2021-01-31" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:bcli="http://brainstorm-cell.com/20211115">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02A_US%2DGAAP%2D2021 -->
<!-- Field: Set; Name: xdx; ID: xdx_038_bcli_brainstorm%2Dcell.com_20211115 -->
<!-- Field: Set; Name: xdx; ID: xdx_04D_20211115_20211115 -->
<!-- Field: Set; Name: xdx; ID: xdx_05E_edei%2D%2DEntityCentralIndexKey_0001137883 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2021-11-15to2021-11-15" name="dei:EntityCentralIndexKey">0001137883</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2021-11-15to2021-11-15" format="ixt:booleanfalse" name="dei:AmendmentFlag">false</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="bcli-20211115.xsd" xlink:type="simple" />
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2021-11-15to2021-11-15">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137883</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-11-15</xbrli:startDate>
        <xbrli:endDate>2021-11-15</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="margin: 0">&#160;</p>

<!-- Field: Rule-Page --><div style="margin-bottom: 3pt; width: 100%"><div style="border-top: Black 2pt solid; border-bottom: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="margin: 0"></p>

<p style="margin: 0">&#160;</p>

<p style="margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>UNITED STATES </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SECURITIES AND EXCHANGE COMMISSION </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Washington, D.C. 20549 </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>FORM <span id="xdx_905_edei--DocumentType_c20211115__20211115_zanFFBRlbeCd"><ix:nonNumeric contextRef="From2021-11-15to2021-11-15" name="dei:DocumentType">8-K</ix:nonNumeric></span> </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CURRENT REPORT </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Pursuant to Section&#160;13 or 15(d)
of the Securities Exchange Act of 1934 </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Date of Report (Date of earliest event reported): <span id="xdx_903_edei--DocumentPeriodEndDate_c20211115__20211115_zwmAwf6Qh2Vf"><ix:nonNumeric contextRef="From2021-11-15to2021-11-15" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate">November 15, 2021</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_908_edei--EntityRegistrantName_c20211115__20211115_zq0ZZaPdwnIb"><ix:nonNumeric contextRef="From2021-11-15to2021-11-15" name="dei:EntityRegistrantName">Brainstorm Cell Therapeutics Inc.</ix:nonNumeric></span> </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><i>(Exact name of registrant as specified
in its charter) </i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr>
    <td style="vertical-align: top; width: 34%; text-align: center"><span style="font-size: 10pt"><b><span id="xdx_908_edei--EntityIncorporationStateCountryCode_c20211115__20211115_z8OwRaE1ND0c"><ix:nonNumeric contextRef="From2021-11-15to2021-11-15" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span> </b></span></td>
    <td style="vertical-align: top; width: 1%">&#160;</td>
    <td style="vertical-align: top; width: 32%; text-align: center"><span style="font-size: 10pt"><b><span id="xdx_90F_edei--EntityFileNumber_c20211115__20211115_zkQN7uLzZDjj"><ix:nonNumeric contextRef="From2021-11-15to2021-11-15" name="dei:EntityFileNumber">001-36641</ix:nonNumeric></span></b></span></td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: top; width: 32%; text-align: center"><span style="font-size: 10pt"><b><span id="xdx_90E_edei--EntityTaxIdentificationNumber_c20211115__20211115_zqyHPMeqOdU2"><ix:nonNumeric contextRef="From2021-11-15to2021-11-15" name="dei:EntityTaxIdentificationNumber">20-7273918</ix:nonNumeric></span></b></span></td></tr>
<tr>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt"><i>(State or other jurisdiction of <br />
incorporation) </i></span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt"><i>(Commission File No.) </i></span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt"><i>(IRS Employer Identification No.) </i></span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 50%; text-align: center"><span style="font-size: 10pt"><b><span id="xdx_900_edei--EntityAddressAddressLine1_c20211115__20211115_zJwhKNslx7Cf"><ix:nonNumeric contextRef="From2021-11-15to2021-11-15" name="dei:EntityAddressAddressLine1">1325 Avenue of Americas</ix:nonNumeric></span>, <span id="xdx_90D_edei--EntityAddressAddressLine2_c20211115__20211115_zPii2kXScbSb"><ix:nonNumeric contextRef="From2021-11-15to2021-11-15" name="dei:EntityAddressAddressLine2">28th Floor</ix:nonNumeric></span></b></span></td>
    <td style="width: 50%">&#160;</td></tr>
<tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-size: 10pt"><b><span id="xdx_90D_edei--EntityAddressCityOrTown_c20211115__20211115_z8dNHJ7MJlk2"><ix:nonNumeric contextRef="From2021-11-15to2021-11-15" name="dei:EntityAddressCityOrTown">New York</ix:nonNumeric></span>, <span id="xdx_901_edei--EntityAddressStateOrProvince_c20211115__20211115_z0rj3U3w5hxa"><ix:nonNumeric contextRef="From2021-11-15to2021-11-15" name="dei:EntityAddressStateOrProvince">NY</ix:nonNumeric></span></b></span></td>
    <td style="text-align: center"><span style="font-size: 10pt"><b><span id="xdx_904_edei--EntityAddressPostalZipCode_c20211115__20211115_zY2mDnjDZg69"><ix:nonNumeric contextRef="From2021-11-15to2021-11-15" name="dei:EntityAddressPostalZipCode">10019</ix:nonNumeric></span></b></span></td></tr>
<tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-size: 10pt"><i>(Address of principal executive offices) </i></span></td>
    <td style="text-align: center"><span style="font-size: 10pt"><i>(Zip Code) </i></span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(<span id="xdx_90D_edei--CityAreaCode_c20211115__20211115_zXLBq6Ol5qL7"><ix:nonNumeric contextRef="From2021-11-15to2021-11-15" name="dei:CityAreaCode">201</ix:nonNumeric></span>) <span id="xdx_90E_edei--LocalPhoneNumber_c20211115__20211115_z9wy6AQ4fS19"><ix:nonNumeric contextRef="From2021-11-15to2021-11-15" name="dei:LocalPhoneNumber">488-0460</ix:nonNumeric></span> </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><i>(Registrant&#8217;s telephone number,
including area code) </i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>N/A </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><i>(Former name or former address, if changed
since last report) </i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">
<tr style="vertical-align: top; text-align: justify">
    <td style="width: 0in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Wingdings"><span id="xdx_908_edei--WrittenCommunications_c20211115__20211115_z6lsww0vCbw6"><ix:nonNumeric contextRef="From2021-11-15to2021-11-15" format="ixt:booleanfalse" name="dei:WrittenCommunications">&#168;</ix:nonNumeric></span></span></td>
    <td style="text-align: justify">Written communications pursuant to Rule&#160;425 under the Securities Act (17 CFR 230.425)</td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">
<tr style="vertical-align: top; text-align: justify">
    <td style="width: 0in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Wingdings"><span id="xdx_903_edei--SolicitingMaterial_c20211115__20211115_z3NCxN3E6dm1"><ix:nonNumeric contextRef="From2021-11-15to2021-11-15" format="ixt:booleanfalse" name="dei:SolicitingMaterial">&#168;</ix:nonNumeric></span></span></td>
    <td style="text-align: justify">Soliciting material pursuant to Rule&#160;14a-12 under the Exchange Act (17 CFR 240.14a-12)</td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">
<tr style="vertical-align: top; text-align: justify">
    <td style="width: 0in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Wingdings"><span id="xdx_90A_edei--PreCommencementTenderOffer_c20211115__20211115_zi7zLRQZI5aa"><ix:nonNumeric contextRef="From2021-11-15to2021-11-15" format="ixt:booleanfalse" name="dei:PreCommencementTenderOffer">&#168;</ix:nonNumeric></span></span></td>
    <td style="text-align: justify">Pre-commencement communications pursuant to Rule&#160;14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">
<tr style="vertical-align: top; text-align: justify">
    <td style="width: 0in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Wingdings"><span style="font-family: Wingdings"><span id="xdx_903_edei--PreCommencementIssuerTenderOffer_c20211115__20211115_znV5ycjYbiD4"><ix:nonNumeric contextRef="From2021-11-15to2021-11-15" format="ixt:booleanfalse" name="dei:PreCommencementIssuerTenderOffer">&#168;</ix:nonNumeric></span></span></span></td>
    <td style="text-align: justify">Pre-commencement communications pursuant to Rule&#160;13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Securities registered pursuant to Section
12(b) of the Act:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="border: Black 1pt solid; width: 40%; text-align: center"><span style="font-size: 10pt">Title of each class</span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; width: 20%; text-align: center"><span style="font-size: 10pt">Trading Symbol(s)</span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; width: 40%; text-align: center"><span style="font-size: 10pt">Name of each exchange on which registered</span></td></tr>
<tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><span style="font-size: 10pt"><span id="xdx_909_edei--Security12bTitle_c20211115__20211115_zYN2Mr8lqbIk"><ix:nonNumeric contextRef="From2021-11-15to2021-11-15" name="dei:Security12bTitle">Common Stock, $0.00005 par value</ix:nonNumeric></span></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 10pt"><span id="xdx_90E_edei--TradingSymbol_c20211115__20211115_z0an0F1ROxzj"><ix:nonNumeric contextRef="From2021-11-15to2021-11-15" name="dei:TradingSymbol">BCLI</ix:nonNumeric></span></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span id="xdx_903_edei--SecurityExchangeName_c20211115__20211115_zrC7aARgXVd7"><ix:nonNumeric contextRef="From2021-11-15to2021-11-15" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">NASDAQ Stock Market LLC</ix:nonNumeric></span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Nasdaq Capital Market)</p></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">Emerging growth company <span style="font-family: Wingdings"><span style="font-family: Wingdings"><span id="xdx_908_edei--EntityEmergingGrowthCompany_c20211115__20211115_zfjJaQmcPCD1"><ix:nonNumeric contextRef="From2021-11-15to2021-11-15" format="ixt:booleanfalse" name="dei:EntityEmergingGrowthCompany">&#168;</ix:nonNumeric></span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. <span style="font-family: Wingdings"><span style="font-family: Wingdings">&#168;</span></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Rule-Page --><div style="margin-top: 3pt; width: 100%"><div style="border-top: Black 1pt solid; border-bottom: Black 2pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item 2.02. Results of Operations and Financial Condition.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 0.5in; background-color: white">Brainstorm Cell Therapeutics
Inc. (the &#8220;Company&#8221;) inadvertently did not timely file a Form 8-K for the press release dated November 15, 2021 related
to its financial and operating results for the quarter ended September 30, 2021. A copy of the press release is being furnished as Exhibit
99.1 to this Report on Form 8-K.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 0.5in; background-color: white">The Company also hosted
a live conference call and webcast on November 15, 2021 to discuss its financial and operating results for the quarter ended September
30, 2021. A transcript of the conference call is being furnished as Exhibit 99.2 to this Report on Form 8-K.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 0.5in; background-color: white">There are no revisions
to the operating results for the quarter ended September 30, 2021 that were presented in the press release and conference call on November
15, 2021.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 0.5in; background-color: white">The
information in this Report on Form 8-K and Exhibit 99.1 and Exhibit 99.2 attached hereto is intended to be furnished and shall not be
deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;),
or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities
Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b>Item 9.01. Financial Statements and Exhibits.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">(d) Exhibits</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="border-bottom: black 1pt solid; width: 10%; padding: 0.25pt 0.25pt 0.5pt">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><b>Exhibit</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><b>No.</b></p></td>
    <td style="padding: 0.25pt 0.25pt 1.25pt; width: 2%">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; width: 88%; padding: 0.25pt 0.25pt 0.5pt"><b>Description</b></td></tr>
  <tr>
    <td style="padding: 0.25pt">&#160;</td>
    <td style="padding: 0.25pt">&#160;</td>
    <td style="padding: 0.25pt">&#160;</td></tr>
  <tr>
    <td style="padding: 0.25pt"><a href="tm223729d1_ex99-1.htm">99.1</a></td>
    <td style="padding: 0.25pt">&#160;</td>
    <td style="padding: 0.25pt"><a href="tm223729d1_ex99-1.htm">Press Release issued by the Company on November 15, 2021, furnished hereto.</a></td></tr>
  <tr>
    <td style="padding: 0.25pt"><a href="tm223729d1_ex99-2.htm">99.2</a></td>
    <td style="padding: 0.25pt">&#160;</td>
    <td style="padding: 0.25pt"><a href="tm223729d1_ex99-2.htm">Transcript of Conference Call by the Company on November 15, 2021, furnished hereto.</a></td></tr>
  <tr>
    <td style="padding: 0.25pt">104</td>
    <td style="padding: 0.25pt">&#160;</td>
    <td style="padding: 0.25pt; vertical-align: top">Cover Page Interactive Data File (embedded within the Inline XBRL document)&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SIGNATURES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 0.5in">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="2"><b>BRAINSTORM CELL THERAPEUTICS INC. </b></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="2">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="width: 50%">&#160;</td>
    <td style="width: 3%">&#160;</td>
    <td style="width: 47%">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>Date: January 28, 2022</td>
    <td>By: </td>
    <td style="border-bottom: Black 1pt solid">/s/ Chaim Lebovits</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>Chaim Lebovits</td></tr>
  <tr style="vertical-align: top">
    <td colspan="2">&#160;</td>
    <td>Chief Executive Officer </td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

</body>
</html>
<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjdEKwjAMRb9g/xD6LNpNFNmbDhVxiowhvhYXpbg1I+2mfpJ/abchhkBI7j25QozElja6RIbLKkshx6oulUPI8IaM5orekez2MfiZ4V1bx8q4fv2BCXkGPTMbT6/+3jtbbbGIQc4ncjqJJMhFHIawPIig0xMyN12gcVqVoEwBJ6aaNTrF7+FDrl5kqHr3SWdkq8nEEI7lIH8gkmEER2rVk/hhIU0TEYz6CsSWqam7mMY6qmBdYuWz7ID+O/gC045JBw== -->
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>tm223729d1_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Exhibit 99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>BrainStorm Cell Therapeutics Announces Third Quarter 2021 Financial
Results and Provides a Corporate Update</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>BrainStorm remains committed to pursuing the best and most expeditious
path forward to facilitate access to NurOwn&reg; for people living with ALS</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Presented important new ALS biomarker data at NEALS meeting showing
significant NurOwn-driven changes across neural biomarkers and that treatment response to NurOwn can be predicted in the trial using biomarker
data and innovative statistical models</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Expanded leadership by naming Stacy R. Lindborg, PhD, EVP and Chief
Development Officer and appointment of Sidney A. Spector, MD, PhD, as SVP, Global Strategy and Medical Affairs and Kim Thacker, MD, as
SVP, Medical Affairs and Clinical Innovation</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Conference call and webcast at 8:00 a.m.&nbsp;Eastern Time today</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">NEW YORK, Nov.&nbsp;15, 2021 -- BrainStorm Cell Therapeutics Inc. (NASDAQ:
BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced financial results for the quarter ended
September&nbsp;30, 2021, and provided a corporate update.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&quot;We made strong progress towards our goal of advancing NurOwn
in ALS and MS over the past months,&quot; said&nbsp;Chaim Lebovits, Chief Executive Officer, Brainstorm Cell Therapeutics. &quot;Our productive
discussions with leading clinical experts continue, and we continue to bring forward new evidence of NurOwn's effectiveness in the scientific
domain, as highlighted by our recent NEALS presentation of Phase 3 ALS data showing that NurOwn drove significant changes in important
neural biomarkers that could be used to predict treatment outcomes within the trial. The insights we have gained from these discussions
have generated strong momentum in our pursuit of the best and most expeditious path forward to bring NurOwn to patients. We also strengthened
our leadership team and increased our manufacturing capacity, supporting our readiness to provide broad patient access as we seek paths
for potential regulatory approval. The devastating and progressive nature of ALS creates an urgent unmet need for patients, and one that
we are fully committed to addressing through NurOwn's continued advancement.&quot;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Third Quarter 2021 and Subsequent Corporate Highlights</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Presented important&nbsp;new Phase 3 ALS Biomarker data&nbsp;showing significant
NurOwn-driven changes across a range of neural biomarkers, and that treatment response in the trial can be predicted using biomarker data
and an innovative statistical model at the 2021 Northeast Amyotrophic Lateral Sclerosis Consortium&reg; (NEALS) conference. &nbsp;This
data furthers our understanding of NurOwn's mechanism of action in ALS and provides additional evidence linking the mechanism of action
to NurOwn's impact on ALS disease progression.&nbsp; Data were presented by Dr.&nbsp;James Berry, MD, Director of the Mass General Hospital
(MGH) multidisciplinary ALS clinic and Principal Investigator in the NurOwn ALS Phase 3 trial.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Presented&nbsp;Phase 2 clinical trial data&nbsp;of NurOwn in progressive
multiple sclerosis (MS) showing safety, preliminary evidence of efficacy, a reduction in neuroinflammatory biomarkers in the cerebrospinal
fluid (CSF), and an increase in neuroprotective biomarkers in the CSF in an oral presentation at the 37<SUP>th</SUP>&nbsp;Congress of
the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS). Data were presented by Dr.&nbsp;Jeffrey Cohen, MD,
Director of Experimental Therapeutics at the Cleveland Clinic Mellen Center for MS and Principal Investigator in the NurOwn MS phase 2
trial.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Highlighted the expansion of BrainStorm's technology portfolio to include
autologous and allogeneic product candidates covering multiple neurological diseases at the&nbsp;2021 Cell&nbsp;&amp; Gene Meeting on
the Mesa.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Presented&nbsp;positive preclinical results&nbsp;suggesting that intrathecal
administration of small extracellular vesicles (sEVs) isolated from MSCs which were induced to secrete increased levels of regenerative
and immunoregulatory factors based on the NurOwn technology platform may have clinical potential as a therapy for acute lung related pathologies
(ARDS) at the NYSCF&nbsp;2021 VIRTUAL Meeting.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Appointed Sidney A. Spector, MD, PhD, as Senior VP, Global Strategy and Medical
Affairs and Kim Thacker, MD, as Senior VP, Medical Affairs and Clinical Innovation.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">o</TD><TD STYLE="text-align: justify">Drs.&nbsp;Spector and Thacker will work together to create a formal global Medical Affairs function as the Company prepares for anticipated
growth.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Expanded the responsibilities of Stacy Lindborg, PhD, Executive Vice President,
named to the new position of Chief Development Officer.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Appointed Menghis Bairu, MD, to the Company's Board of Directors.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Increased commercial manufacturing capacity with the receipt of Good Manufacturing
Practice (GMP) approval from the Israel Ministry of Health for three state-of-the-art cleanrooms leased by the Company at the Tel Aviv
Sourasky Medical Center (&quot;Sourasky Hospital&quot;) in Tel Aviv,&nbsp;Israel.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Financial Results for the Three Months Ended September&nbsp;30,
2021</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Cash, cash equivalents, and short-term bank deposits were approximately
$28 million as of September&nbsp;30, 2021, compared to approximately $35 million on June&nbsp;30, 2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Research and development expenses, for the three months ended September&nbsp;30,
2021 and 2020 were approximately $3.6 million and $4.1 million, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">General and administrative expenses for the three months ended September&nbsp;30,
2021 and 2020 were approximately $1.7 million and $2.6 million, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Net loss for the three months ended September&nbsp;30, 2021 was approximately
$5.3 million, as compared to a net loss of approximately $4.5 million for the three months ended September&nbsp;30, 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Net loss per share for the three months ended September&nbsp;30, 2021
and 2020 was $0.15 and $0.14, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Conference Call and Webcast</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 50%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="border-top: Black 1pt solid; padding-right: 6pt; padding-left: 6pt; border-right: Black 1pt solid; border-left: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Monday, November&nbsp;15, 2021, at 8:00 a.m.&nbsp;Eastern Time</B></FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-left: Black 1pt solid; border-top: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 6pt; padding-left: 6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">From the U.S.:&nbsp;</FONT></TD>
    <TD STYLE="border: Black 1pt solid; padding-right: 6pt; padding-left: 6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">888-506-0062</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-left: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 6pt; padding-left: 6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">International:&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 6pt; padding-left: 6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">973-528-0011&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-left: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 6pt; padding-left: 6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Entry
Code: &nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 6pt; padding-left: 6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">837509</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Webcast URL:
https://www.webcaster4.com/Webcast/Page/2354/43351</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Those that wish to listen to the replay of the conference call can
do so by dialing the numbers below. The replay will be available for 14 days.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 40%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-left: Black 1pt solid; border-top: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 6pt; padding-left: 6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
the U.S.:&nbsp;</FONT></TD>
    <TD STYLE="border: Black 1pt solid; padding-right: 6pt; padding-left: 6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">877-481-4010&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-left: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 6pt; padding-left: 6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">International:&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 6pt; padding-left: 6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">919-882-2331&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-left: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 6pt; padding-left: 6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Replay Passcode:&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 6pt; padding-left: 6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">43351</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About NurOwn&reg;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The NurOwn<SUP>&reg;</SUP>&nbsp;technology platform (autologous MSC-NTF
cells) represents a promising investigational therapeutic approach to targeting disease pathways important in neurodegenerative disorders.
MSC-NTF cells are produced from autologous, bone marrow-derived mesenchymal stem cells (MSCs) that have been expanded and differentiated
ex vivo. MSCs are converted into MSC-NTF cells by growing them under patented conditions that induce the cells to secrete high levels
of neurotrophic factors (NTFs). Autologous MSC-NTF cells are designed to effectively deliver multiple NTFs and immunomodulatory cytokines
directly to the site of damage to elicit a desired biological effect and ultimately slow or stabilize disease progression.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About BrainStorm Cell Therapeutics Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">BrainStorm Cell Therapeutics Inc. is a leading developer of innovative
autologous adult stem cell therapeutics for debilitating neurodegenerative diseases. The Company holds the rights to clinical development
and commercialization of the NurOwn<SUP>&reg;</SUP>&nbsp;technology platform used to produce autologous MSC-NTF cells through an exclusive,
worldwide licensing agreement. Autologous MSC-NTF cells have received Orphan Drug designation status from the U.S. Food and Drug Administration
(FDA) and the European Medicines Agency (EMA) for the treatment of amyotrophic lateral sclerosis (ALS). BrainStorm has completed a Phase
3 pivotal trial in ALS (NCT03280056); this trial investigated the safety and efficacy of repeat-administration of autologous MSC-NTF cells
and was supported by a grant from the California Institute for Regenerative Medicine (CIRM CLIN2-0989). BrainStorm completed under an
investigational new drug application a Phase 2 open-label multicenter trial (NCT03799718) of autologous MSC-NTF cells in progressive multiple
sclerosis (MS) and was supported by a grant from the National MS Society (NMSS).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">For more information, visit the company's website at&nbsp;www.brainstorm-cell.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Safe-Harbor Statement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Statements in this announcement other than historical data and information,
including statements regarding future NurOwn<SUP>&reg;</SUP>&nbsp;manufacturing and clinical development plans, constitute &quot;forward-looking
statements&quot; and involve risks and uncertainties that could cause BrainStorm Cell Therapeutics Inc.'s actual results to differ materially
from those stated or implied by such forward-looking statements. Terms and phrases such as &quot;may,&quot; &quot;should,&quot; &quot;would,&quot;
 &quot;could,&quot; &quot;will,&quot; &quot;expect,&quot;&nbsp;&quot;likely,&quot; &quot;believe,&quot; &quot;plan,&quot; &quot;estimate,&quot;
 &quot;predict,&quot; &quot;potential,&quot; and similar terms and phrases are intended to identify these forward-looking statements. The
potential risks and uncertainties include, without limitation, BrainStorm's need to raise additional capital, BrainStorm's ability to
continue as a going concern, the prospects for regulatory approval of BrainStorm's NurOwn<SUP>&reg;&nbsp;</SUP>treatment candidate, the
initiation, completion, and success of BrainStorm's product development programs and research, regulatory and personnel issues, development
of a global market for our services, the ability to secure and maintain research institutions to conduct our clinical trials, the ability
to generate significant revenue, the ability of BrainStorm's NurOwn<SUP>&reg;</SUP>&nbsp;treatment candidate to achieve broad acceptance
as a treatment option for ALS or other neurodegenerative diseases, BrainStorm's ability to manufacture, or to use third parties to manufacture,
and commercialize the NurOwn<SUP>&reg;</SUP>&nbsp;treatment candidate, obtaining patents that provide meaningful protection, competition
and market developments, BrainStorm's ability to protect our intellectual property from infringement by third parties, heath reform legislation,
demand for our services, currency exchange rates and product liability claims and litigation; and other factors detailed in BrainStorm's
annual report on Form&nbsp;10-K and quarterly reports on Form&nbsp;10-Q available at&nbsp;http://www.sec.gov. These factors should be
considered carefully, and readers should not place undue reliance on BrainStorm's forward-looking statements. The forward-looking statements
contained in this press release are based on the beliefs, expectations and opinions of management as of the date of this press release.
We do not assume any obligation to update forward-looking statements to reflect actual results or assumptions if circumstances or management's
beliefs, expectations or opinions should change, unless otherwise required by law. Although we believe that the expectations reflected
in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Contacts:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Contacts<BR>
</B>Investor Relations:<BR>
John Mullaly<BR>
LifeSci Advisors, LLC<BR>
Phone: +1 617-429-3548&nbsp;<BR>
jmullaly@lifesciadvisors.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Media:<BR>
Mariesa Kemble&nbsp;&nbsp;<BR>
kemblem@mac.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>BRAINSTORM CELL THERAPEUTICS&nbsp;INC. AND SUBSIDIARIES</U></B></FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>INTERIM CONDENSED CONSOLIDATED BALANCE SHEETS</U></B></FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>U.S. dollars in thousands</B></FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(Except share data)</B></FONT></P>



<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">September&nbsp;30,</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">December&nbsp;31,</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2021</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2020</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">U.S.&nbsp;$&nbsp;in&nbsp;thousands</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-decoration: underline">ASSETS</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Current Assets:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 74%; font: 10pt Times New Roman, Times, Serif; text-align: left">Cash and cash equivalents</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">25,695</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">37,829</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Short-term deposit (Note&nbsp;4)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">2,114</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">4,107</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Other accounts receivable</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">85</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">304</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Prepaid expenses and other current assets (Note 5)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">50</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1,002</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Total current assets</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">27,944</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">43,242</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Long-Term Assets:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Prepaid expenses and other long-term assets</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">32</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">26</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Operating lease right of use asset (Note 6)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">5,338</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">6,872</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Property and Equipment, Net</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1,224</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1,119</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Total Long-Term Assets</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">6,594</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">8,017</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Total assets</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">34,538</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">51,259</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-decoration: underline; text-align: left">LIABILITIES AND STOCKHOLDERS' EQUITY</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Current Liabilities:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Accounts payable</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">2,739</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">5,417</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Accrued expenses</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">387</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,261</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Operating lease liability (Note 6)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,735</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">2,655</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Other accounts payable</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">985</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1,900</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Total current liabilities</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">5,846</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">11,233</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Long-Term Liabilities:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Operating lease liability (Note 6)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">3,766</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">4,562</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Total long-term liabilities</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">3,766</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">4,562</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Total liabilities</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">9,612</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">15,795</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Stockholders' Equity:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Stock capital: (Note&nbsp;7)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">12</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">12</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Common Stock of $0.00005 par value - Authorized: 100,000,000 shares at
    September&nbsp;30, 2021 and December&nbsp;31, 2020 respectively; Issued and outstanding: 36,277,953 and 35,159,977 shares at
    September&nbsp;30, 2021 and December&nbsp;31, 2020 respectively.</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Additional paid-in-capital</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">192,384</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">184,655</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Treasury stocks</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(116</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(116</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Accumulated deficit</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(167,354</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(149,087</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Total stockholders' equity</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">24,926</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">35,464</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Total liabilities and stockholders' equity</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">34,538</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">51,259</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>BRAINSTORM CELL THERAPEUTICS&nbsp;INC. AND SUBSIDIARIES</U></B></FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>INTERIM CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (UNAUDITED)</U></B></FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>U.S. dollars in thousands</B></FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(Except share data)</B></FONT></P>



<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Nine months ended</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Three months ended</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">September&nbsp;30,</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">September&nbsp;30,</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2021</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2020</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2021</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2020</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Unaudited</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Unaudited</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Operating expenses:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 48%; font: 10pt Times New Roman, Times, Serif; text-align: left">Research and development, net (Note&nbsp;8)</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">11,558</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">13,509</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">3,618</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">1,867</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">General and administrative</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">6,769</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">6,684</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1,659</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">2,618</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Operating loss</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(18,327</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(20,193</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(5,277</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(4,485</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Financial expenses (income), net</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(60</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(197</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">59</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">3</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Net loss</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(18,267</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(19,996</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(5,336</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(4,488</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Basic and diluted net loss per share from continuing operations</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(0.51</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(0.70</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(0.15</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(0.14</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Weighted average number of shares outstanding used<BR> in computing basic and diluted net loss per share</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">36,140,130</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">28,695,540</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">36,304,878</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">31,154,101</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>3
<FILENAME>tm223729d1_ex99-2.htm
<DESCRIPTION>EXHIBIT 99.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 99.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Transcript of</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">BrainStorm Cell Therapeutics,&nbsp;Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Third Quarter 2021 Earnings Call</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">November&nbsp;15, 2021</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Participants</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Michael Wood - Investor Relations, LifeSci Advisors</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Chaim Lebovits - Chief Executive Officer, BrainStorm
Cell Therapeutics,&nbsp;Inc.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Alla Patlis - Interim Chief Financial Officer,
BrainStorm Cell Therapeutics,&nbsp;Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Stacy Lindborg - Executive Vice President&nbsp;&amp;
Chief Development Office, BrainStorm Cell Therapeutics,&nbsp;Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Ralph Kern - President&nbsp;&amp; Chief Medical
Officer, BrainStorm Cell Therapeutics,&nbsp;Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">David Setboun - Executive Vice President&nbsp;&amp;
Chief Operating Officer, BrainStorm Cell Therapeutics,&nbsp;Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Operator</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Good day, ladies and gentlemen, and welcome to
the BrainStorm Cell Therapeutics Third Quarter 2021 Earnings Call. At this time, all participants have been placed on listen-only mode
and the floor will be opened for questions and comments after the presentation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">It is now my pleasure to turn the floor over to
your host, Michael Rice of LifeSci Advisors. Sir, the floor is yours.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Michael Wood - Investor Relations, LifeSci
Advisors</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Good morning and thank you for joining us. Before
we begin the opening remarks,&nbsp;I&rsquo;d like to remind listeners that this conference call contains numerous statements, descriptions,
forecasts, and projections regarding BrainStorm Cell Therapeutics and its potential future business operations and performance, statements
regarding the market potential for the treatment of neurodegenerative diseases, such as ALS and MS, the sufficiency of the company&rsquo;s
existing capital resources for continuing operations in 2021 and beyond, the safety and clinical effectiveness of the NurOwn technology
platform, clinical trials of NurOwn and related clinical development programs, and the company&rsquo;s ability to develop strategic collaborations
and partnerships to support their business planning efforts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Forward-looking statements are subject to numerous
risks and uncertainties, many of which are beyond BrainStorm&rsquo;s control, including the risks and uncertainties described from time-to-time
in its filings with the SEC. The company&rsquo;s results may differ materially from those projected on today&rsquo;s call. The company
undertakes no obligation to publicly update any forward-looking statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Joining me on the call today will be Chaim Lebovits,
CEO of BrainStorm; Alla Patlis,&nbsp;Interim Chief Financial Officer; and in addition, Dr.&nbsp;Stacy Lindborg, Executive VP and Chief
Development Officer; Dr.&nbsp;Ralph Kern, President and Chief Medical Officer; and Dr.&nbsp;David Setboun, Executive VP and Chief Operating
Officer will also be on the call and will be available to answer your questions during the Q&amp;A session.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">So I&rsquo;d now like to turn the call over to
Mr.&nbsp;Lebovits. Please, go ahead.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Chaim Lebovits - Chief Executive Officer,
BrainStorm Cell Therapeutics,&nbsp;Inc.</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Thanks, Michael and thanks all listening, who
are joining us to discuss our third quarter financial results and corporate highlights. I&rsquo;ll update on NurOwn in both the ALS and
progressive MS programs that I want to cover today, as well as some important additions to our management team.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">First, with regard to our lead program NurOwn
in ALS, we remain committed to advancing this program and pursuing the best and most expeditious path forward to enable patient access.
Patients and advocates are changing the landscape of ALS to match the urgency of their disease. Given the important changes, we are in
active dialogue with regulators around our regulatory plan and we will share this as soon as appropriate. We recently presented important
new biomarker data from our Phase 3 trial in ALS and poster presentation  at the Northeast ALS Consortium or NEALS, in October. The
presenter was Dr.&nbsp;James Berry, the Principal Investigator of NurOwn trial and the Director of the Massachusetts General Hospital
multidisciplinary ALS clinic.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Biomarker analysis, as a reminder, were pre-specified
in the statistical analysis plan and was completed and submitted to the FDA prior to unblinding of the trial. These involved collecting
CSF samples from all participants and measuring pre-specified biomarkers at certain time points from baseline through week 20. The results
of these analysis shows that NurOwn treatment resulted in significant changes across many biomarkers pertaining to neurodegeneration,
neuroinflammation and neuroprotection, while levels of these biomarkers remain stable and unchanged following treatment of a placebo.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Another important analysis that was pre-specified
and was designed to help us understand how the observed changes in biomarkers with NurOwn related to clinical response observed in the
child. As shared in the NEALS presentation, Dr.&nbsp;Berry presented results from a stepwise regression model, which identified a set
of biomarkers, spanning a pathway of neuroprotection, neuroinflammatory, and neurodegeneration biomarkers that accurately predicted clinical
response in the child with over 80% accuracy. So not only did we observe significant changes in biomarkers important for ALS with NurOwn,
but they are meaningful and helping us understand who responded to treatment in the study.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The results further our understanding of NurOwn&rsquo;s
mechanism of action in ALS, which target multiple pathways and provide additional evidence linking the mechanism of actions to NurOwn&rsquo;s
impact and ALS disease progression. In the future, this information will also help future studies of use CSF biomarkers, advanced ALS
science. We do, of course, plans to share them with the FDA and other regulatory authorities. A hyperlink to this poster was included
in the press release, which is available on the publication section on the BrainStorm&rsquo;s website. I would encourage investors to
review it.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Turning now to our progressive multiple sclerosis
program, the results from our Phase 2 study of NurOwn in progressive MS were features in an oral presentation at the 37th Congress of
the European Committee of Treatment and Research in Multiple Sclerosis or ECTRIMS. We announced positive top line results from the study
in March&nbsp;of this year and this was our first opportunity to share the results with a broader neurology community at a major international
MS meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The presentation was given by Dr.&nbsp;Jeffrey
Cohen, the Director of Experimental Therapeutics at the Cleveland Clinic, Mellen Center for MS and Principal Investigator in the NurOwn
MS Phase 2 trial. Dr.&nbsp;Cohen shared that the study achieved its primary endpoint of safety and tolerability. In addition, we demonstrated
a reduction of neuroinflammatory biomarkers and an increase in neuroprotective biomarkers in CSF. In addition, we observed consistent
improvement across MS functional outcome measures, including walking, upper extremity function, vision and cognition. BrainStorm was the
main sponsor for this study, but we had additional financial support for the biomarker analyses from the National Multiple Sclerosis Society
Fast-Forward Program.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We&rsquo;re actively working on a development
plan in order to advance the progressive MS program through registration and approval. We&rsquo;re currently holding discussions with
CMS experts and seeking guidance from the FDA to determine next steps. We have submitted the manuscript summarizing the trial results
for publication.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Based on developing an innovative
exosome-based platform technology, which utilizes exosomes derived from NurOwn, we have been exploring acute respiratory distress
syndrome or ARDS as the potential first indications. Our pre-clinical data from this program will be published in The Journal of
Stem Cell Research&nbsp;&amp; Therapy at the beginning of the year, and Dr.&nbsp;Revital Aricha, Vice President of R&amp;D had an
opportunity to present this data at the New York Stem Cell Foundation of 2021 virtual meeting, which took place in October.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The results showed that NurOwn exosomes were capable
of increasing blood oxygen saturation and reducing lung pathology inflammatory infiltrates and levels of pro-inflammatory cytokines in
two animal models of ARDS. We showed that neural exosomes were superior to na&iuml;ve MSC exosomes in all examined parameters.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Finally,&nbsp;I want to mention some important
additions to the management team and to the Board of Directors. We announced last week that we had appointed Dr.&nbsp;Sidney Spector as
Senior Vice President, Global Strategy and Medical Affairs and Dr.&nbsp;Kim Thacker as Senior Vice President of Medical Affairs and Clinical
Innovation. Dr.&nbsp;Spector was most recently Clinical Associate Professor of Neurology at the University of Arizona College of Medicine
and worked in the industry developing CNS drugs at Novartis, Elan Pharma, and Pfizer. Dr.&nbsp;Spector brings more than 20 years of experience
in pharma and biotech, most recently VP of Medical Affairs at UroGen and previously at Sanofi Aventis, Pfizer, and Roche among others. Both Dr.&nbsp;Spector
and Dr.&nbsp;Thacker will work together to create a formal global medical affairs function as we prepare BrainStorm for anticipated growth.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, we expanded the
responsibilities of Dr.&nbsp;Stacy Lindborg, Executive Vice President, appointing her to the new position of Chief Development
Officer. In this role, she will build a leadership team for development of regulatory affairs, to support clinical development in
multiple areas and technologies. We also recently announced Dr.&nbsp;Menghis Bairu was appointed to the Board of Directors in
October. Dr.&nbsp;Bairu is a physician, entrepreneur, business executive, editor, author, and philanthropist. He is the Founder,
Chairman, and CEO of Proxenia Venture Partners, which provides capital, talent management, and access to a global network of experts
to companies in late preclinical and early-stage clinical development in biotech. He is also Chairman and CEO of Bairex, an
international medical education and market research organization focused on Africa and the Middle East.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At this critical juncture in the history of Brainstorm
Cell Therapeutics, these appointments will expand the leadership team with capabilities that complement our already strong team to help
us as we advance our development portfolio of innovative treatments. I want to formally welcome Sidney, Kim and Menghis to BrainStorm
and congratulate Stacy on her new responsibility.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">I will now turn the call over to Alla Patlis who
will review our financial.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Alla Patlis - Interim Chief Financial Officer,
BrainStorm Cell Therapeutics,&nbsp;Inc.</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Thank you, Chaim. [Technical Difficulty] it&rsquo;s
my pleasure now to walk you through our third quarter of 2021 financial results. BrainStorm&rsquo;s cash, cash equivalents, and short-term
bank deposits were approximately $28 million as of September&nbsp;30, 2021, and this compares to the approximately $35 million on June&nbsp;30,
2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Research and development expenses for the three
months ended September&nbsp;30, 2021 and 2020 were approximately $3.6 million and $4.1 million respectively. Research and development
expense, net for the third quarter of 2020, was $1.9 million, which includes participation from IIA and other grants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">General and Administrative expenses for the three
months ended September&nbsp;30, 2021 and 2020 were approximately $1.7 million and $2.6 million, respectively. Net loss for the three months
ended September&nbsp;30, 2021 was approximately $5.3 million or $0.15 per share as compared to net loss of approximately $4.5 million
or $0.14 per share for the three months ended September&nbsp;30, 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Next to you, Chaim.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Chaim Lebovits - Chief Executive Officer,
BrainStorm Cell Therapeutics,&nbsp;Inc.</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Thank you so much, Alla. Mike, would you please
read now the questions we have received from investors?</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Michael Wood - Investor Relations, LifeSci
Advisors</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Yes, the first question directed to you Chaim.
What do you say to those who say that you have ethical obligation to make NurOwn available now for ALS patients? Do you feel that the
Phase 3 trial met a high ethical standard? And do you think most patients with ALS would agree with you?</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Chaim Lebovits - Chief Executive Officer,
BrainStorm Cell Therapeutics,&nbsp;Inc.</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Thank you, Michael. We hear and understand the
urgency expressed in this question. Because we learn urgency every day directly from patients through social media for access to NurOwn.
This is a complicated question with lots of dimensions. Let me start by acknowledging that broad actions for NurOwn at this point in the
development cycle can only come through a regulatory approval. However, we engaged with regulators and took action to establish a small
EAP, Expanded Access Program, which demonstrates our urgency to make NurOwn available beyond the completion of the Phase 3 trial.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We treated the maximum number of patients we&rsquo;re
able to do with the company&rsquo;s resource limited. The FDA gave its full support for the EAP and the dosing for this protocol has now
been completed. And this will provide additional data into the effect of NurOwn based on a longer treatment period. And while we haven&rsquo;t
released any data from this program, Dr.&nbsp;Merit Cudkowicz testified at the recent ALS Congressional hearings, and I quote &quot;There
are reports from people in the NurOwn trial and Expanded Access Program of improvements in function, not something we typically see or
hear in ALS&quot;. We are excited to see what we will learn from this program.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Now turning to the component of your questions
that inquires about BrainStorm&rsquo;s ethical obligation, there&rsquo;s no question in our mind that this trial meets an extremely high
ethical standard, even though rolling up a coalition of representatives of ALS communities in most ALS trials made it more challenging
to conduct the study. We truly believe in the effectiveness of NurOwn and we&rsquo;re working urgently to providing to those could benefit,
even as we continue our research to learn more. As we noted in our earlier remarks, we have submitted the full data set for publication
in a peer reviewed journal and expect to be able to share these results widely upon publication. We certainly hope that people and families
living with ALS know that we have their best interest in our heart. Next question please.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Michael Wood - Investor Relations, LifeSci
Advisors</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">What is the status of the NurOwn application to
the FDA, will the application be submitted or considered early?</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Chaim Lebovits - Chief Executive Officer,
BrainStorm Cell Therapeutics,&nbsp;Inc.</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Stacy, would you take this one please.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Stacy Lindborg - Executive Vice President&nbsp;&amp;
Chief Development Office, BrainStorm Cell Therapeutics,&nbsp;Inc.</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Sure. We&rsquo;ve been clear in our communications
every time that before we would make a decision around the filing of a BLA application of NurOwn that we intend to first publish the
results from our trial in a peer reviewed journal and second to meet with important members of the ALS community who were not involved
in the conduct of our Phase 3 trial. And as Chaim just shared on this call, we&rsquo;ve made great progress with these goals and immediately
after the publication is in print, we will be prepared to speak to our plans for BLA filing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Chaim Lebovits - Chief Executive Officer,
BrainStorm Cell Therapeutics,&nbsp;Inc.</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Thank you.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Michael Wood - Investor Relations, LifeSci
Advisors</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Next question, please provide an update on the
identification of ALS biomarkers?</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Chaim Lebovits - Chief Executive Officer,
BrainStorm Cell Therapeutics,&nbsp;Inc.</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Stacy, yours still.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Stacy Lindborg - Executive Vice President&nbsp;&amp;
Chief Development Office, BrainStorm Cell Therapeutics,&nbsp;Inc.</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Sure. So in the Phase 3 trial, we generated a
unique set of biomarker data through the collection and analysis of seven CSF samples over time going from baseline to 20 weeks in all
study participants. And as Chaim just reflected, we observed significant improvements in multiple CSF biomarkers of neuro-inflammation,
neuro-degeneration and neurotrophic factor support with NurOwn treatment while placebo remained unchanged and stable. A few examples and
all of these are at week 20, which is the final time point that we collected biomarker data on with VEGF, which is a marker -- an important
marker of neuroprotection, we observed a two-fold increase with NurOwn treated patients, while placebo remained unchanged. With MCP-1,
a marker of NurOwn inflammation, the values were 74% with NurOwn treated patients of placebo, which was a remarkable reduction over the
placebo values.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Finally, neurofilament light, a marker of neurodegeneration
was 84% of placebo values in NurOwn treated patients at that last time period. As we shared in our prepared remarks, Dr.&nbsp;James Berry,
Principal Investigator from Mass General, recently presented the results of a stepwise regression model at NEALS, which identified a set
of biomarkers spanning these really important pathways of neuroprotection, neuroinflammation and neurodegeneration. And this model, accurately
predicted the primary clinical response our primary endpoint in the trial with over 80% accuracy. So not only are there changes observed
in these important biomarkers for ALS, but they&rsquo;re meaningful in helping us understand who responded to treatment in the study.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">So in summary, our detailed biomarker analyses
support the proposed mechanism of action of NurOwn and provide additional evidence linking the mechanism of action to NurOwn&rsquo;s impact
on ALS with this progression. And a thorough analysis of this data will be published separately in a peer reviewed manuscript.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Chaim Lebovits - Chief Executive Officer,
BrainStorm Cell Therapeutics,&nbsp;Inc.</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Thank you so much.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Michael Wood - Investor Relations, LifeSci
Advisors</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The next question relates to the earlier clinical
and preclinical programs, please provide an update on the trials and data associated with MS and Parkinson&rsquo;s disease?</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Chaim Lebovits - Chief Executive Officer,
BrainStorm Cell Therapeutics,&nbsp;Inc.</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Thank you. Ralph?</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Ralph Kern - President&nbsp;&amp; Chief
Medical Officer, BrainStorm Cell Therapeutics,&nbsp;Inc.</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Yeah. Thank you for the question, Michael. I&rsquo;ll
start with our MS program. As you recall in Chaim&rsquo;s prepared comments, the MS Phase 2 clinical trial was completed earlier this
year and the data was recently presented in an oral presentation at the 37th ECTRIMS Congress by Dr.&nbsp;Jeff Cohen from the Cleveland
Clinic. The high level summary was that the study achieved the primary endpoint of safety and tolerability, it also demonstrated a reduction
of neuroinflammatory biomarkers, and an increase of neuroprotective biomarkers in the cerebrospinal fluid, as well as consistent improvement
across MS functional outcome measures, including measures of locking, upper extremity function, vision, and cognition. We&rsquo;re now
holding discussions with key MS experts and seeking guidance from the FDA to determine next steps. As mentioned earlier, we&rsquo;ve also
submitted a manuscript for peer review and publication.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">I&rsquo;ll now address the question about Parkinson&rsquo;s
disease. As you know, Parkinson&rsquo;s is a disease that we remain quite interested in. We believe NurOwn&rsquo;s demonstrated mechanism
of action could motivate this as a future clinical target but for now, we don&rsquo;t have an update on this indication. To date, our
clinical priorities have been focused on first, ALS; second, progressive MS; and third, Alzheimer&rsquo;s disease. And given our size
of the company and the resources we can bring to bear on all our work, we&rsquo;re being very careful to not move too quickly with other
indications. Thank you.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Michael Wood - Investor Relations, LifeSci
Advisors</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">And then regarding Alzheimer&rsquo;s and ARDS,
can you provide updates here, please?</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Ralph Kern - President&nbsp;&amp; Chief
Medical Officer, BrainStorm Cell Therapeutics,&nbsp;Inc.</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Absolutely. So regarding Alzheimer&rsquo;s, in
the Q2 earnings call, we shared that with the recent approval of Aduhelm. And with other advances in the Alzheimer&rsquo;s disease competitive
landscape, we wanted to step back and strategically consider our clinical goals before proceeding with a clinical study in Alzheimer&rsquo;s
disease with NurOwn. Alzheimer&rsquo;s disease remains a prioritized indication and as such, as we&rsquo;ve already engaged with a few
of the top Alzheimer&rsquo;s KOLs in the US, we&rsquo;ve shared our data with them. We&rsquo;ve been consulting with them on our clinical
plans. Their feedback has been exciting and very helpful. We also expect to have an update to share publicly very shortly.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">And finally, regarding ARDS, Chaim made a very
full description of our results. What I can add is that, as we shared our prepared -- as we shared earlier, we&rsquo;ve demonstrated the
beneficial effects of our derived exosomes in acute lung injury model, in addition to demonstrating superior effects of these exosomes
compared to naive MSCs exosomes. All of these results, including the publication in stem cell research and therapy journal, are available
on our websites.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We&rsquo;ve continued to do further research using
a Bleomycin model of lung injury, which is characterized by extensive inflammation, fibrosis an injury to the lung tissue. And we look
forward to sharing new insights, including how they fit together with our priorities going forward.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Chaim Lebovits - Chief Executive Officer,
BrainStorm Cell Therapeutics,&nbsp;Inc.</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Thanks so much.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Michael Wood - Investor Relations, LifeSci
Advisors</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">And then finally, we have one question relating
to business development. Please provide an update on the plans for joint ventures or partnerships with other companies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Chaim Lebovits - Chief Executive Officer,
BrainStorm Cell Therapeutics,&nbsp;Inc.</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">David?</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>David Setboun - Executive Vice President&nbsp;&amp;
Chief Operating Officer, BrainStorm Cell Therapeutics,&nbsp;Inc.</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Sure. So, partnering is an integrated part of
our strategy. We are actively engaging with a variety of potential partners, which include mid-sized and leading pharmaceutical companies.
And we are engaging for both, NurOwn in ALS and MS and as well, a more recent exosome program. Thank you.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Michael Wood - Investor Relations, LifeSci
Advisors</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Sure. Paul, would you open the line for questions
from investors on the line?</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Operator</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Certainly. Ladies and gentlemen, the floor is
now open for questions. [Operator Instructions] And the first question is coming from Jason McCarthy from Maxim Group. Jason, your line
is live.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Q: </B>Hey, thanks for taking my question this
is Michael Rabinowitz on the line for Jason. So my first question,&nbsp;I&rsquo;d like to gauge your thoughts on the exosomes platform
and how that might best be applied. Whether it can be thought of as a next gen follow-up in indications where NurOwn is already successful
or if it&rsquo;s more targeted towards indications which may have an increased benefit from using what is essentially a snapshot of the
signaling activity of the cells?</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Chaim Lebovits -Chief Executive Officer,
BrainStorm Cell Therapeutics,&nbsp;Inc.</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Hi. Thanks, Michael. Ralph, you want to take this
question?</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Ralph Kern - President&nbsp;&amp; Chief
Medical Officer, BrainStorm Cell Therapeutics,&nbsp;Inc.</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Yeah. Thank you for the question. Yeah, we do
exosomes as potentially next-generation but I think that there are some unique advantages of exosomes that are worth mentioning. First
of all, the ease of formulation and logistics are definitely an advantage, including potentially cost. There are unique advantages of
exosomes in terms of delivery in certain unique situations. For example, in the lung, sending products through the airwaves that are very
small-size of viral particles like exosomes is very advantageous to reach the most distant parts of the lungs. So there are some biophysical
reasons why we have applied that in the lung, particularly in the acute lung injury model. There are still questions around exosomes that
we&rsquo;re working on and we intend to leverage the pre-clinical knowledge to make the best decision about the optimal application of
exosomes, both in lung disease and potentially in other diseases as well.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Q: </B>All right. Thank you. And then I&rsquo;d
like to follow-up on that. Just do you have any thought as to how you might formulate the exosome platform for delivery to the lungs,
like nebulization or dry powder, have you given any thought to that for when it eventually might move into humans?</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Chaim Lebovits - Chief Executive Officer,
BrainStorm Cell Therapeutics,&nbsp;Inc.</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Yes, so I will take that. Definitely we give a
lot of thoughts and we are looking at the different pathways and you mentioned those pathways and inhalation is definitely something we&rsquo;re
looking at or intrathecally. But yes, when we&rsquo;ll get into humans, we will have to take that decision. We&rsquo;re doing preclinical
trials in order to confirm the best way of target. A very good question, this is one of the major questions on exosomes trials. And I
will just add, of course, for the CNF space, exosomes also may be beneficial for diseases like Parkinson&rsquo;s mentioned before, as
you probably can overcome the blood-brain barrier issues.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Q: </B>Thank you very much. And then just one
more on the biomarker data,&nbsp;I wanted to see if you can provide a bit more color on how you could leverage the biomarker data and
its correlation to outcomes in your discussions with regulators and your further development within ALS?</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Chaim Lebovits - Chief Executive Officer,
BrainStorm Cell Therapeutics,&nbsp;Inc.</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Thank you very much. I&rsquo;ll let Stacy answer
that.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>Stacy Lindborg - Executive Vice President&nbsp;&amp; Chief Development
Office, BrainStorm Cell Therapeutics,&nbsp;Inc.</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Yes,&nbsp;I&rsquo;m happy to respond that. Thank
you. Well, as Chaim already described in his prepared remarks, these were pre-specified analyses and were submitted to the FDA before
we unblinded our trial. So, these kinds of models, which are really important, the fact that they&rsquo;re pre-specified, of course, these
will become part of discussions with regulators as we progress either with informal discussions or formal discussions as they proceed.
The important part of the model that Chaim described to you is that it really leverages the relationships observed in the data. And it&rsquo;s
machine learning in the sense that it doesn&rsquo;t involve our judgment or kind of preconceived beliefs about biomarkers, it doesn&rsquo;t
allow that to interfere. So, this model that Chaim was just speaking about really is harnessing the information what we&rsquo;ve observed
about the treatment effects on these important biomarkers and they&rsquo;re selected into this model to help provide the most accurate
explanation or prediction of the patients that responded.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Q: </B>Thank you very much for taking my questions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Chaim Lebovits - Chief Executive Officer,
BrainStorm Cell Therapeutics,&nbsp;Inc.</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Yes. Thanks so much Michael. Next question please
operator.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Operator</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Thank you. The next question is coming from David
Bautz from Zacks Small Cap Research. David, your line is live.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Q: </B>Hey, good morning, everybody. So, my
first question is about MS. So, clearly, there&rsquo;s a lot of MS drugs that are out there right now and now that you&rsquo;ve got some
data in hand,&nbsp;I&rsquo;m curious what your thoughts are on where NurOwn might fit in that treatment landscape?</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Chaim Lebovits - Chief Executive Officer,
BrainStorm Cell Therapeutics,&nbsp;Inc.</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dr.&nbsp;Kern?</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Ralph Kern - President&nbsp;&amp; Chief
Medical Officer, BrainStorm Cell Therapeutics,&nbsp;Inc.</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Yeah, David, thank you for that question. I think
it&rsquo;s worth just describing again, the unmet need in progressive MS. As you know, most of the therapeutic success in MS has been
for relapsing remitting MS and it&rsquo;s been remarkable over the past 20 years how well that&rsquo;s gone. There still is a very large
unmet need in progressive MS, both clinically, patients continue to deteriorate slowly, despite the use of the optimal and most recent
successful treatments and also, there&rsquo;s an unmet biologic need. If we think that that&rsquo;s where we&rsquo;re targeting, in terms
of the compartmentalized inflammation in the brain, delivering the treatment directly into the spinal fluid and changing the microenvironment.
And also delivering repair molecules and neurotrophic factors. We think that&rsquo;s what we saw in our Phase 2 trial. We&rsquo;re very
excited about the results. There&rsquo;s huge potential and a lot of interest among experts, and also among international organizations
to see what the next steps might be. So we&rsquo;re carefully considering all that. We&rsquo;re very optimistic about where we go next
and we want to consider that carefully, receive the feedback from the agency, obviously, and other regulatory bodies and then make the
best decision about what the next steps will be. And we&rsquo;ll have an announcement once we&rsquo;ve gotten there. So thanks for that
question again.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Q: </B>Okay, thanks for that. And I did have
one question about the ALS biomarker data. I just want to make sure that I understand. So of those biomarkers that were identified, was
each of them correlated to outcome of NurOwn treatment or was it the biomarkers as a group?</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Chaim Lebovits - Chief Executive Officer,
BrainStorm Cell Therapeutics,&nbsp;Inc.</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">I know, David, that an analyst will come up with
that question understanding the correlation in the group and the models. We have an expert on the line, Dr.&nbsp;Stacy Lindborg it&rsquo;s
all yours.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Stacy Lindborg - Executive Vice President&nbsp;&amp;
Chief Development Office, BrainStorm Cell Therapeutics,&nbsp;Inc.</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Thank you. So as to provide maybe a little bit
more clarity into the methodology again, so all biomarkers that were collected as part of the study were possible to be included in this
model. So the methodology allowed any of these biomarkers that were contributing and that the explanatory value towards this prediction
to enter the model. And for any one marker to come into the model, it had to be statistically significant at a level of a P-value less
than 0.5 and to remain in the model, it also had to remain statistically significant, so with a P-value is less than 0.5. So, these kinds
of iterative models, basically allow terms to come and go and then ultimately to land on the optimal model that has the strongest prediction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">All of the terms, all of the biomarkers that are
part of it, which, of course, were reported in the poster at the NEALS meeting recently are contributing simultaneously significant information
towards this prediction. And Chaim spoke of the accuracy, so what we presented in this poster is an area under the curve, it&rsquo;s coming
from a receiver operating characteristic and it really gives us &ndash; it&rsquo;s a wonderful metric, it&rsquo;s a diagnostic metric
that allows us to evaluate how accurate the prediction is or, in this case, how good these biomarkers are in discriminating participants
that responded in the child versus those that didn&rsquo;t.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">And as a rule&nbsp;of thumb, if you have above
80%, this is this is quite high classification, and in our model that we spoke of and what we reported on NEALS, we had an area under
the curve from receiver operating curve of 82.5. And we actually see this estimate increase when we focus on models that are predictive
of each therapy separately and this will be the focus of our biomarker paper that we will be hopefully submitting it in the near future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Chaim Lebovits - Chief Executive Officer,
BrainStorm Cell Therapeutics,&nbsp;Inc.</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">David,&nbsp;I&rsquo;m sure you would like to understand
more. I think I am just -- you&rsquo;re going to have an offline conversation with Dr.&nbsp;Lindborg. I&rsquo;m not sure all of us there&rsquo;s
a following these models, right.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Q: </B>Okay. No, that&rsquo;s fine. And then
I have one more. Last quarter you mentioned that the hospital exemption program was currently not ongoing in Israel and I&rsquo;m just
curious, if there&rsquo;s similar type programs being planned for other jurisdictions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Chaim Lebovits - Chief Executive Officer,
BrainStorm Cell Therapeutics,&nbsp;Inc.</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">I&rsquo;ll give you a short answer. Yes and can&rsquo;t
elaborate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Q: </B>Okay, fair enough. Thanks for taking
the questions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Chaim Lebovits - Chief Executive Officer,
BrainStorm Cell Therapeutics,&nbsp;Inc.</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Sure.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Operator</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Thank you. [Operator Instructions] And the next
question is coming from Paula Smith [ph]. Paula, your line is live.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Q: </B>Good morning. First, as a mom,&nbsp;I
just wanted to express my gratitude to BrainStorm. I am just so grateful that my son was given the opportunity to be in the trial and
that BrainStorm is just giving us hope and access to treatment for ALS and hopefully, we can continue it. I just want to say my son is
32 years old and he spent in the Phase 3 trial and in the Expanded Access trial. While he was in both, he stabilized, he regained function
and his ALSFRS score has improved.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">So the biggest improvement for Josh was his FVC
had improved to over 40%, which to me is amazing. He&rsquo;s still able to walk. He can still climb stairs. He can still get into his
jeep. He can eat. He has no problem swallowing. And he&rsquo;s still able to use his hands. And this is four years from his onset. Our
doctors here all believe that NurOwn works and we are in close contact with other people that are receiving the EAP and their experiences
and how they stabilized. So my question is, can you speak about the results in EAP now that everyone has received the three doses, and
will BrainStorm, be using the EAP data to speak and seek approval for NurOwn?</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Chaim Lebovits - Chief Executive Officer,
BrainStorm Cell Therapeutics,&nbsp;Inc.</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">So Paula, thank you for your question. I wasn&rsquo;t
expecting this,&nbsp;I thought it&rsquo;s a private investor. As you know, we are not yet and as we said in the comments at the beginning
of the call, we cannot yet talk to the EAP results. Very warming to hear what you&rsquo;re saying and you&rsquo;re describing. And I do
hope that we should be able to share with you some good news very soon. That&rsquo;s all I can say for the time being and very happy that
your son is doing well and being stable or even better, our hearts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Q: </B>It is. It&rsquo;s amazing to me, it&rsquo;s
a miracle, and I just wanted to continue.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Chaim Lebovits - Chief Executive Officer,
BrainStorm Cell Therapeutics,&nbsp;Inc.</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Well, we all want the same. We&rsquo;re working
very hard at that.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Q: </B>Thank you.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Chaim Lebovits - Chief Executive Officer,
BrainStorm Cell Therapeutics,&nbsp;Inc.</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">You&rsquo;re very welcome.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Operator</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Thank you. And the next question is coming from
Michelle Lorenz&lrm; from Voices  for ALS. Michelle, your line is live.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Q: </B>Thank you. Hard to follow up after Paula.
Last month, at ECTRIMS, when Dr.&nbsp;Cohen from Cleveland Clinic spoke about the results in progressive MS,&nbsp;I found it quite profound
because he used the words that NurOwn repaired and restored function. And he did that in an interview with NeurologyLive. And it struck
me, that those words mirrored what the patient&rsquo;s had been saying in the NurOwn trial since 2015 back in Phase 2. So, those words
are subjective. What I want to know is, if you can speak to any of the similarities in the biomarker data between the MS study and the
ALS studies, and if any of that biomarker data from one or the other helps to validate the evidence of efficacy in the other disease?</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Chaim Lebovits - Chief Executive Officer,
BrainStorm Cell Therapeutics,&nbsp;Inc.</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Thank you. Very good question. I will allow both
Ralph and Stacy to comment on this because of different aspects to the question to answer. Ralph?</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Ralph Kern - Chief Medical Officer, BrainStorm
Cell Therapeutics,&nbsp;Inc.</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Sure. I&rsquo;ll start and handoff to Stacy. So,
thank you again for that, a really insightful question. The answer is, yes, but I think it requires some explanation and we&rsquo;ll start
today and maybe we can take this offline. There are two main areas where we observe significant biomarker changes and Stacy gave a very
clear and detailed description of that a few minutes ago, just to highlight a couple of points.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">One is that in the area of neuroprotection, this
is something that is deficient in ALS, and also in progressive MS, as it is in many neurological diseases where the repair mechanisms
are failing. And that&rsquo;s part of the known disease processes. We believe that repairing the nervous system requires restoring this
neuroprotection function. And we know that the cells that we have primed in our technology platform are able to do that better than unprimed
MSCs and certainly better than other therapies, because that&rsquo;s the prime function of the cells is to deliver these molecules.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The second area is inflammation. We know that,
literally every day, there&rsquo;s more data suggesting that all neurodegenerative diseases have inflammation. There&rsquo;s slight differences
in terms of which cells participate and how it influences the outcomes. But we know that, there&rsquo;s a big commonality between ALS
and progressive MS regarding the inflammatory pathways. And again, there we see consistent changes in inflammatory biomarkers. The advantage
of looking at CSF or cerebrospinal fluid is that, we get a direct view of what&rsquo;s happening in the brain microenvironment. So I&rsquo;ll
pause there, and I&rsquo;ll hand off to Stacy to answer the other parts of the question.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Stacy Lindborg - Executive Vice President&nbsp;&amp;
Chief Development Office, BrainStorm Cell Therapeutics,&nbsp;Inc.</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Well Ralph, you covered this,&nbsp;I think, extremely
well in terms of really linking not only what we believe about the deficits that are known across neurodegenerative diseases in known
biomarkers and the similarities of what we&rsquo;re observing with NurOwn across these two devastating illnesses. I think the point that
I would add is that, anytime we&rsquo;re looking at why we believe a treatment is working and of course, biomarker data is critical across
all diseases and giving us insight into biologically what&rsquo;s happening. One of the important aspects has been to understand also
the treatment relationship with clinical symptoms and in your question about, are we seeing similar repair and function restored, this
is also a component that is extremely important. In the progressive MS trial, we had responder criteria that showed that patients were
improving in their clinical function across many of those the known clinical measures, which Ralph enumerated before.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Similarly, we can observe in our ALS data, and
of course, the formal analyses that we&rsquo;ve done really linking biomarkers and clinical data also show this important link, that not
only do we see important changes, either slowing down the decline, or in some cases improving declining. But we see similarly that the
biomarkers are going in the direction that one would expect with an effective treatment. So we&rsquo;re seeing reductions in neuroinflammation
and we&rsquo;re seeing improvement in neuroprotection. So I think it&rsquo;s a very insightful comment and a really great question for
us to continue to consider.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Chaim Lebovits - Chief Executive Officer,
BrainStorm Cell Therapeutics,&nbsp;Inc.</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Thank you.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Operator</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Thank you. And there were no more questions in
queue at this time. I would like to have the call back to the BrainStorm Cell Therapeutics management team for any closing remarks.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Chaim Lebovits - Chief Executive Officer,
BrainStorm Cell Therapeutics,&nbsp;Inc.</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Well, thank you, Paul. No further remarks. Thanks,
everyone for listening in. Looking forward for a very exciting quarter. Good luck everyone.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Operator</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Thank you, ladies and gentlemen. This does conclude
today&rsquo;s conference. You may disconnect at this time and have a wonderful day. Thank you for your participation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 14; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>bcli-20211115.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.11a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: +aA5w7xRiXgen8uLa3ZcWa+GubOdzZR+CYkxtmB8bVnqLyMuoHXzui14jrfmMVQG -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:srt-types="http://fasb.org/srt-types/2021-01-31" xmlns:bcli="http://brainstorm-cell.com/20211115" elementFormDefault="qualified" targetNamespace="http://brainstorm-cell.com/20211115">
    <annotation>
      <appinfo>
	<link:roleType roleURI="http://brainstorm-cell.com/role/Cover" id="Cover">
	  <link:definition>00000001 - Document - Cover</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:linkbaseRef xlink:type="simple" xlink:href="bcli-20211115_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="bcli-20211115_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2021q4" schemaLocation="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" />
    <import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd" />
    <import namespace="http://fasb.org/us-types/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2021" schemaLocation="https://xbrl.sec.gov/country/2021/country-2021.xsd" />
    <import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd" />
    <import namespace="http://fasb.org/srt-types/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>bcli-20211115_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.11a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>bcli-20211115_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.11a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://brainstorm-cell.com/role/Cover" xlink:href="bcli-20211115.xsd#Cover" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://brainstorm-cell.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.4</span><table class="report" border="0" cellspacing="2" id="idm139789309954056">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Nov. 15, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Nov. 15,  2021<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36641<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Brainstorm Cell Therapeutics Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001137883<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">20-7273918<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">1325 Avenue of Americas<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">28th Floor<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">New York<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NY<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">10019<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">201<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">488-0460<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.00005 par value<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">BCLI<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>tm223729d1_8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2021q4"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="bcli-20211115.xsd" xlink:type="simple"/>
    <context id="From2021-11-15to2021-11-15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001137883</identifier>
        </entity>
        <period>
            <startDate>2021-11-15</startDate>
            <endDate>2021-11-15</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:EntityCentralIndexKey contextRef="From2021-11-15to2021-11-15">0001137883</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="From2021-11-15to2021-11-15">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="From2021-11-15to2021-11-15">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="From2021-11-15to2021-11-15">2021-11-15</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="From2021-11-15to2021-11-15">Brainstorm Cell Therapeutics Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2021-11-15to2021-11-15">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="From2021-11-15to2021-11-15">001-36641</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="From2021-11-15to2021-11-15">20-7273918</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2021-11-15to2021-11-15">1325 Avenue of Americas</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="From2021-11-15to2021-11-15">28th Floor</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="From2021-11-15to2021-11-15">New York</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2021-11-15to2021-11-15">NY</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2021-11-15to2021-11-15">10019</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2021-11-15to2021-11-15">201</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2021-11-15to2021-11-15">488-0460</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="From2021-11-15to2021-11-15">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="From2021-11-15to2021-11-15">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="From2021-11-15to2021-11-15">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="From2021-11-15to2021-11-15">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="From2021-11-15to2021-11-15">Common Stock, $0.00005 par value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2021-11-15to2021-11-15">BCLI</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2021-11-15to2021-11-15">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="From2021-11-15to2021-11-15">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M(SB\ ^X&N+Y2RAX'[H.X^'_&Z!]02P,$%     @ 6($\5)^@&_"Q @  X@P
M  T   !X;"]S='EL97,N>&ULW5=M:]LP$/XK0C]@;F)JXI$8MD!AL(U"\V%?
ME5AV!'KQ9+ES^NNGLVPG:75EW8>QS:')W3VZNT=W)YFN6W>2_.'(N2.]DKK=
MT*-SS?LD:0]'KEC[SC1<>Z0R5C'G55LG;6,Y*UMP4C)9WMQDB6)"TV*M.W6G
M7$L.IM-N0V]H4JPKH\^6E :#7\H4)X],;NB62;&W8EC+E)"G8%Z"X6"DL<1Y
M*GQ#%V!IGP*\"!JP'.,HH8T%8Q(RA._]N/P9,&FM5X64,\$E#89BW3#GN-5W
M7AD6#\87$!GEW:GQ#&O+3HOE+3T[##\^R=[8DMLYS8).IF(M>05TK*B/\.M,
MDP#HG%%>* 6KC68#A\EC%'S8 Y?R 5KXK;J*W5<D].)3"6T@L-5)](1&,80)
M"L2_C!9B7X2]_:VPI!&/QGWL_&[TH'_OC./WEE>B'_2^FO-CT1=X=-8T\O1!
MBEHK'O;^RPF+-9O\R-%8\>2SP:0<O(%;2AZY=>)P:?EA6;/CO9NFJ:]PSLM_
MD/.?K7/--;=,7I+VH_\W5_DMC)/Q]%P<T:L#.EL)7(0;^A7N5WGF0/:=D$[H
M43N*LN3ZQ3GUX1W;^PO\*KY?7_**==+M9G!#S_(77HI.Y?.J>ZC+N.HL?X;[
M:)'-M[#/)73)>UYN1]76^T$D7O!9QP<<GB-WPQ-',)^ Q1' L#P8 \PG>&%Y
M_J?]K-#]! SCMHHB*]1GA?H$KQBR'3Y8GKA/[I_X3O,\3;,,J^AV&V6PQ>J6
M9? 7CX9Q P\L#V1Z6ZWQ;N,3\OH<8#U];4*PG>*3B.T4KS4@\;J!1Y['NXWE
M 0^L"]CL0/YX'IBIN$^:0E<Q;M@)QI$\QQ"8Q?B,9AE2G0P^\?Y@IR1-\SR.
M !9GD*88 J<11S &P %#TG1X#SY['R73>RHY_U=3_ 102P,$%     @ 6($\
M5)>*NQS     $P(   L   !?<F5L<R\N<F5L<YV2N6[#, Q ?\70GC 'T"&(
M,V7Q%@3Y 5:B#]@2!8I%G;^OVJ5QD L9>3T\$MP>:4#M.*2VBZD8_1!2:5K5
MN %(MB6/:<Z10J[4+!XUA]) 1-MC0[!:+#Y +AEFM[UD%J=SI%>(7->=I3W;
M+T]!;X"O.DQQ0FE(2S,.\,W2?S+W\PPU1>5*(Y5;&GC3Y?YVX$G1H2)8%II%
MR=.B':5_'<?VD-/IKV,BM'I;Z/EQ:%0*CMQC)8QQ8K3^-8+)#^Q^ %!+ P04
M    " !8@3Q4JL0B%C,!   B @  #P   'AL+W=O<FMB;V]K+GAM;(U1T6["
M, S\E2H?L!:T(0U17D#;D*8-C8GWT+K4(HDKQX6-KY_;JAK27O:4W-FZW%T6
M%^+3@>B4?'D78FYJD6:>IK&HP=MX1PT$G53$WHI"/J:Q8;!EK '$NW2:9;/4
M6PQFN1BUMIS> A(H!"DHV1%[A$O\G7<P.6/$ SJ4[]ST=P<F\1C0XQ7*W&0F
MB35=7HCQ2D&LVQ5,SN5F,@SVP(+%'WK7F?RTA]@S8@\?5HWD9I:I8(4<I=_H
M]:UZ/(,N#Z@5>D(GP&LK\,S4-AB.G8RF2&]B]#V,YU#BG/]3(U45%K"FHO40
M9.B1P74&0ZRQB28)UD-N5G0&[O+H YMRR"9JZJ8IGJ,.>%,.]D9/)508H'Q3
MF:B\]E-L.>F.7F=Z_S!YU!Y:YU;*O8=7LN48<?R>Y0]02P,$%     @ 6($\
M5"0>FZ*M    ^ $  !H   !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<[61
M/0Z#, R%KQ+E #50J4,%3%U8*RX0!?,C$A+%K@JW+X4!D#IT8;*>+7_OR4Z?
M:!1W;J"V\R1&:P;*9,OL[P"D6[2*+L[C,$]J%ZSB688&O-*]:A"2*+I!V#-D
MGNZ9HIP\_D-T==UI?#C]LCCP#S"\7>BI160I2A4:Y$S":+8VP5+BRTR6HJ@R
M&8HJEG!:(.+)(&UI5GVP3TZTYWD7-_=%KLWC":[?#'!X=/X!4$L#!!0    (
M %B!/%1ED'F2&0$  ,\#   3    6T-O;G1E;G1?5'EP97-=+GAM;*V334[#
M,!"%KQ)E6R4N+%B@IAM@"UUP 6-/&JO^DV=:TMLS3MI*H!(5A4VL>-Z\SYZ7
MK-Z/$;#HG?78E!U1?!0"50=.8ATB>*ZT(3E)_)JV(DJUDUL0]\OE@U#!$WBJ
M*'N4Z]4SM')OJ7CI>1M-\$V9P&)9/(W"S&I*&:,U2A+7Q<'K'Y3J1*BY<]!@
M9R(N6%"*JX1<^1UPZGL[0$I&0[&1B5ZE8Y7HK4 Z6L!ZVN+*&4/;&@4ZJ+WC
MEAIC JFQ R!GZ]%T,4TFGC",S[O9_,%F"LC*30H1.;$$?\>=(\G=560C2&2F
MKW@ALO7L^T%.6X.^D<WC_0QI-^2!8ECFS_A[QA?_&\[Q$<+NOS^QO-9.&G_F
MB^$_7G\!4$L! A0#%     @ 6($\5 =!36*!    L0   !
M ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    " !8@3Q4@=O P^X
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M<W1Y;&5S+GAM;%!+ 0(4 Q0    ( %B!/%27BKL<P    !,"   +
M      "  6L/  !?<F5L<R\N<F5L<U!+ 0(4 Q0    ( %B!/%2JQ"(6,P$
M "("   /              "  500  !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4
M    " !8@3Q4)!Z;HJT   #X 0  &@              @ &T$0  >&PO7W)E
M;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4    " !8@3Q499!YDAD!  #/
M P  $P              @ &9$@  6T-O;G1E;G1?5'EP97-=+GAM;%!+!08
1    "0 ) #X"  #C$P     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>122</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="tm223729d1_8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://brainstorm-cell.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="tm223729d1_8k.htm">tm223729d1_8k.htm</File>
    <File>bcli-20211115.xsd</File>
    <File>bcli-20211115_lab.xml</File>
    <File>bcli-20211115_pre.xml</File>
    <File>tm223729d1_ex99-1.htm</File>
    <File>tm223729d1_ex99-2.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2021q4</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>14
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "tm223729d1_8k.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "tm223729d1_8k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "bcli-20211115_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "bcli-20211115_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "bcli-20211115.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd"
     ]
    }
   },
   "elementCount": 59,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2021q4": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 122,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "bcli",
   "nsuri": "http://brainstorm-cell.com/20211115",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "baseRef": "tm223729d1_8k.htm",
      "contextRef": "From2021-11-15to2021-11-15",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00000001 - Document - Cover",
     "role": "http://brainstorm-cell.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "baseRef": "tm223729d1_8k.htm",
      "contextRef": "From2021-11-15to2021-11-15",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of changes contained within amended document.",
        "label": "Amendment Description"
       }
      }
     },
     "localname": "AmendmentDescription",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://brainstorm-cell.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://brainstorm-cell.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AnnualInformationForm": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.",
        "label": "Annual Information Form"
       }
      }
     },
     "localname": "AnnualInformationForm",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://brainstorm-cell.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditedAnnualFinancialStatements": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.",
        "label": "Audited Annual Financial Statements"
       }
      }
     },
     "localname": "AuditedAnnualFinancialStatements",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://brainstorm-cell.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://brainstorm-cell.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CountryRegion": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Region code of country",
        "label": "Country Region"
       }
      }
     },
     "localname": "CountryRegion",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://brainstorm-cell.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://brainstorm-cell.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAccountingStandard": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.",
        "label": "Document Accounting Standard"
       }
      }
     },
     "localname": "DocumentAccountingStandard",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://brainstorm-cell.com/role/Cover"
     ],
     "xbrltype": "accountingStandardItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r11",
      "r13",
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://brainstorm-cell.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://brainstorm-cell.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://brainstorm-cell.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://brainstorm-cell.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentPeriodStartDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.",
        "label": "Document Period Start Date"
       }
      }
     },
     "localname": "DocumentPeriodStartDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://brainstorm-cell.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://brainstorm-cell.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentRegistrationStatement": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a registration statement.",
        "label": "Document Registration Statement"
       }
      }
     },
     "localname": "DocumentRegistrationStatement",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://brainstorm-cell.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentShellCompanyEventDate": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date of event requiring a shell company report.",
        "label": "Document Shell Company Event Date"
       }
      }
     },
     "localname": "DocumentShellCompanyEventDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://brainstorm-cell.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentShellCompanyReport": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.",
        "label": "Document Shell Company Report"
       }
      }
     },
     "localname": "DocumentShellCompanyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://brainstorm-cell.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://brainstorm-cell.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://brainstorm-cell.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://brainstorm-cell.com/role/Cover"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://brainstorm-cell.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://brainstorm-cell.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine3": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 3 such as an Office Park",
        "label": "Entity Address, Address Line Three"
       }
      }
     },
     "localname": "EntityAddressAddressLine3",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://brainstorm-cell.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://brainstorm-cell.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://brainstorm-cell.com/role/Cover"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://brainstorm-cell.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://brainstorm-cell.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.",
        "label": "Entity Bankruptcy Proceedings, Reporting Current"
       }
      }
     },
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://brainstorm-cell.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://brainstorm-cell.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://brainstorm-cell.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://brainstorm-cell.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://brainstorm-cell.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Elected Not To Use the Extended Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://brainstorm-cell.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://brainstorm-cell.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://brainstorm-cell.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://brainstorm-cell.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://brainstorm-cell.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPrimarySicNumber": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.",
        "label": "Entity Primary SIC Number"
       }
      }
     },
     "localname": "EntityPrimarySicNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://brainstorm-cell.com/role/Cover"
     ],
     "xbrltype": "sicNumberItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://brainstorm-cell.com/role/Cover"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://brainstorm-cell.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://brainstorm-cell.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://brainstorm-cell.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://brainstorm-cell.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://brainstorm-cell.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://brainstorm-cell.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_Extension": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Extension number for local phone number.",
        "label": "Extension"
       }
      }
     },
     "localname": "Extension",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://brainstorm-cell.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://brainstorm-cell.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_NoTradingSymbolFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a security having no trading symbol.",
        "label": "No Trading Symbol Flag"
       }
      }
     },
     "localname": "NoTradingSymbolFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://brainstorm-cell.com/role/Cover"
     ],
     "xbrltype": "trueItemType"
    },
    "dei_OtherReportingStandardItemNumber": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.",
        "label": "Other Reporting Standard Item Number"
       }
      }
     },
     "localname": "OtherReportingStandardItemNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://brainstorm-cell.com/role/Cover"
     ],
     "xbrltype": "otherReportingStandardItemNumberItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://brainstorm-cell.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://brainstorm-cell.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://brainstorm-cell.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_Security12gTitle": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(g) registered security.",
        "label": "Title of 12(g) Security"
       }
      }
     },
     "localname": "Security12gTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://brainstorm-cell.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://brainstorm-cell.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SecurityReportingObligation": {
     "auth_ref": [
      "r9"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.",
        "label": "Security Reporting Obligation"
       }
      }
     },
     "localname": "SecurityReportingObligation",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://brainstorm-cell.com/role/Cover"
     ],
     "xbrltype": "securityReportingObligationItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://brainstorm-cell.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://brainstorm-cell.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://brainstorm-cell.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 3
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r10": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r11": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  },
  "r12": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r13": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r14": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r15": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r16": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r17": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r18": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  },
  "r19": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "g"
  },
  "r6": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12, 13, 15d"
  },
  "r7": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r8": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r9": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "15",
   "Subsection": "d"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>15
<FILENAME>0001104659-22-008997-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001104659-22-008997-xbrl.zip
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M*WP9V#?UZ#VF4.@X6SA#\C!PYRDS-"W=&C!!1&)3K^V>.T\FWUP*&@2</9Y
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MM5106[X[ID8G<T3,[=%9+A=6\$R" A^(2)0LO!MYB+L+NL'=69Z1;'IQ]J6
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MK/"WP7DELC.HKL.<(E,24];QH/I#D+TZIY*2_?(R59-;F:39,.7R2)CA&GN
M<V/:[6^:ZJ0KKX,*KT,J(E)^LPYZ39QC-DK^:.7Q\IEI-3,J9BN_)K;U:[;(
M1R=17LOE"FNETB:&MIX7&SU1,#4K(1*N>[/%>Z352G.**!$.&T:F4E$KE+9(
M.JPL'GGAP'JQ?B:)2&[WPC;9HWO",C61_T24Y'V:9[M<E3G)D_AX+].NE0_B
MXNV=7HU%#9(]E/=52 Q@^CU6%XF]HMRXRL<()9:U8K&:;)LWX:ZB58]6)G(V
M5_$\&B=1=6JHA5K_!%Q4O&DPKI\8U&_WM@N%Q.W9?"KE\W.G<1_.ZYGG@T*V
M/ V%/'2)EL=N:II7,YQXCQA.T#?9VGAN&9-&^J=<>U8XB/DV2SQ\5'I5M5Q^
M[NAQQ?3:NN#IC,Q8=MCTUW/>7$[(JIFN6-+*\Q9^(B4VD59E,/?*SQH2FR0A
MEFE*+$P77AA<;=?/VA?M7KO5E95VO:O&G^=7%\W63?=WTOKKMMW[>\?#DCN[
ML W75]-,XPO5$86S)+B_K0O;N.AD/<S.&M/)9J9FS>G$=R8R'A7G]-TN1A^7
MB[:R5IIW)#;"'ECQB1?L#S=@TQ.OS2/T*HZUJBNC]8YC#LSIRERIZ4;LDW4<
M;4U[MGVH$ZT\Z)0DV?>M^KA27AGN-E>Q/'*"\2!C_ITV67),4IM/PD^.LC:,
M1GFMEEMO$O;&Q)]>F]-K3B, ";^]W96IEN:RCQ*IL&%4RH,E72QNCUA81R!P
M>IZ=A *W?V$;YLT]9I&NS,5+9%Q1.ZHDFFC3J532RI4M*C#YQ>5GTS* Q%A-
M1,0'H=*6B8B5U: I$?#^C;\MQV(UK9+_$"5 RT5;OJP=S7=LVHB]L0X_KNL[
M^@^\M)2YWN^B<,&?)&[<EBYLP]PXQ5WAK6O'\5Y51Q_D..Y#2.2M0MRF',3M
MG38<RW)L(C>),R"?<MD<_%/&"\W('34#1C)X]?+(<4$$&#AH3LO)_V13>H]0
M7P(PW^6<8*=I><'RPP;@^%4.;V'"NY[X'3,GGTD;[_V3%S([@8_W4:'%>$R*
M%:UP=*35RD7Q7;&LY<LUK79TM&0(LCLNFW=V8;]4Z7P0'._LPC9%&"],MYO>
M&XN-)C+<SBA+YF-HX%I!*U:31IMOQ%ZUM+'91*NP]'MX]6/@3HB'ULP&!EM6
M0./]?'ZIK4,^ADNT(JQMLB;Y0')OF4,FR-MEG?'(44U=UP,+KZ8'9]1@ Z[S
MI('*.V1MY4@KEE??0R7)O'@'C4HU+3=?Y;(J&FWXD<0S/1&\F?,*)LXKEL=[
MO[[J_A4,N,32^T))J\VWP4O:)&PLP8IEK519=_>;33SH?T9<Q,[_12!ZU\5'
MTF EH=7CU0:_M,'*H;@ ^73%MZJ_><!HJ-A5\-?BOODNB EFZ^R8E.6U\()-
M8I?4QV^FQLOGYZZF%K?4/W>+YNLNK(]-WW<9_9'ILX'C HQC 7,<I,H"B!#,
MUTX90\PA8D8B8Z74C+/6-MP8?G)[>G93;W>ZO:N;2W&W-^F=MV[JUZW;7KO1
ME<ML=QI9V;GG]JS;;K;K-^W6[ET1#ZAH=WJMFS;@X:K3;'6Z+;R?MM.]NF@W
MZ[T6RA_X<=GJ]+KDZ@M\=7E]TSJ'Y]K?6N3BJMLE^[>=^FVS#<\>[!QZ\,Y<
MD.JF25V/<)O$KLK=H57NMW[J#$4<I@H0@_KT8,'Z9M<8B88YL2 4B-A5U_5F
ML]WY^L=>;D_\W;VN-\*_9Y6ICB@>>P!4^-MG$EU$^)J;"/=>9OHFET(K==;A
M-B,6S#/R"+,-9KPBOK'QEYZO%9.]D<O6B\KD"O37TF@^^2EA]ZU!Y4ZP>V&=
M-,+$OEUB\'4C[S4])A+D)9RW19RW$\)TK0KOUJ:!P?W$0MY\#&[XV6F\14+8
M)#(IYDH6EBQL\Y/9'SL?5<&J4O45L:I%@-XPCU%7'XEC4(/=,=-15U39X:UO
M<BW5N5R>,%[VJFC94Z1\PX O.D"+ GMO'GC:\:E<GCO57!+8BWGM R*YJ)5S
M<\>1"9*7BN2B5LDGC+QB1M:JE;GTO17@>'-3W!]Q$;XR&\Q14Z@<:EC<YIZ/
MYNE=TD;VS<Q6T8XJZ[UM+Z'26ZA4F2^=2ZBT853*:Y7G\Z$2*OUB*A46F3#;
MV='JA<'-'?*)DX4E"]N0A6U1\-9TO(]20EW5BH6EWO#S0:JH"SDM7YMK2IX@
M[EG$E;&?48*W5^.MI)7F;S!9 MZVHRSY"[>IK7-J1@=K9)_;NF.Q Q%!3\S[
M-S-69?4WKB3ER>_0T+6UE28G]'D]?9( QL:3:/>NCDGB&,G"DH5M8QQCW67X
M'>:_*YJ1%&ZK*$EA_HAY!97;2S3$/B2=:EJMMHX^*@F=WAD#*A83,FT\F3#D
MM([>(AO?0O)1=CBC'M=E2B<W ^R99RN%2\;,5777 ]>QB Z3<SO TP5'GC,X
M=J*5W\6>N6SYV5JD1(C\>BH=/1M@3*CTZZF4?_9Z](1*&T"E=32=VY:3(<4"
MWQFB!R]/ ?"P,9(=8/TZ7NFB[DB)W:A" H\9)V<WI]CU17>L<2!._/LO4.2[
MQ+NO",,NLUM=1<N7<EJ^N Z-L.RP^4<E6J&J56IEK5Q*B+8]1(.=5@1OJ'J4
M](;<(J+EM7RYI.5SZW!K%H:T=Z!)9.4SN1H+[_J87%#/WYR>D>MKX'AX=M7\
M^Q1_.>]=7IS^/U!+ P04    " !8@3Q45L[QL"@Z   3)P$ %0   '1M,C(S
M-S(Y9#%?97@Y.2TR+FAT;>U]VY(;Q['M.R+P#[T=WGK"C"A*LF511PYR2$JT
M29'FT%+H./Q00!> XG1WP7V9(?CU)U=FUJ4!#$7Y6/* FAV.30W0Z*ZN2UY7
MKOSJVU?/GGX]G7SU[:/[#^G? O_WU:LGKYX^^OJKC^5?^O9C_?JK!\\?_EB<
MO_KQZ:/_\[NE;_HOBT_N;/KBE:MM5WQGKXJ7OC;-3#Z8%>>V=<O?T0_IIR]^
M[N_N%;5I5Z[YLL"E=^X5O7W3GYC*K>BCUJW6_>^^_NK!UX_>K-W<]<6?_G1Z
M]ZN/']"P7_P2#US8IK?M[[[^J)EWFWN_\$->M:;I%JVC*_SR%W[6@]:XYKSW
M;5V<V:HJ7JUM:S9VZ-VBF\G;/FD6I[_T&Z]=6Q9_&TQ+?Q9W[]S]I'ADVL8U
MJZXX,U7U"S_^.W]IZ[EMY7T_^7S&0_B//?07WC:OAZYWRRT?AQ<T@V[A-J;I
MN__H<?BUWN&96ZR-K8H?O"^+D^))<VD[VIW%2UN9WOF&[O;4+>WYPA7WRTO7
M^;;[I8=TMC:N+I[:N;]T?4>#.EL[NRP>O;$+.B:7MGB^7+J%;6=%.DS3R;M.
MTZ\SE?>KRA0O3%^YCF>2MCJ]APS^L6M,LW"FBH.?3OZ[HB .^[PWBRTM<E/.
M?;NBD:>)_IY&6KQH;>=*.KDRI(],O;E'T\VO]=!>VLIO:OI67RQ?E/_J:[TT
MU69=_-6V#;W2H7?0E7EF2[<PU71R8%?]5U_@H;ET)?V@G_NA^7G+\GQ#(^Y)
MFA\Z*K_.2_V*,OBKOW\M+^S;KS[^^]='*8:_@?@MS7965*9T=#?3E,6*5K>R
M=+AF_.>5K1:^MD7OIY-^;=^YI,5/:?C3XGY?]&L253T-EAY -]ADRJQ8&]II
M<VN;8E.9A2T+WQ0DV7K;G/BFVA:U+^UT@G%A+,O*D]*X<G27N2W\QC;TBR5]
M]*^!] GT"+\"C1^R@OY88ECXY8;V,7W$RN;XMM^3OJ I;/Q546]IHJSIAA8K
M5/0#"9XT,V3PM+QP6S^TQ=IW_:P(JO<ECK-?[NG9T^+<T<E--Z$GX>?=\4V3
MG-+WMS6FDV1L'/.)KCT?N4*.B6DNL(!\+EY[Q]\,M,P/+'U"A^D*!XYNS$N.
M,X0+6DM/NX@R^J.V^]?@[Y5T%B]XH]'WI+KU:-JVPW/T9"]\L[2M;6A[+7"^
MZ>^>1 ;MUZ&VK1^ZHJ-S9_E$SHK2B@_$"S&=8$@+T^$;C'[3^M=V(2>YM2O3
MEAC<.T40?@8#;N-I9#ULG^70XWC,A\XUMNOPCJU)TH'^HJ?2?,.,2$.;3M(#
M,3.8#]OGM_4B2OK6FIYM$3I-C1U:$E$K3(IAM5FZCLXGEK$;%NO"=,7]I^?\
MX&?G<LRZ >K2T8QM<0M\1!*+Y.%6IYW&8M_03&,H"[-Q/3V=Y!<=R@7M%XP#
M<^R: 1=D;T=KRB(8#YO;K6]*?:!9VGXKHK&B#4'+5-CE$A-]:66*9!C?#>WS
M*]H8=K%N?.57V^F$Q'*/Z9JEG_8M30?_1J_'C5N<+IL]H,R,-EK656MJ7>0#
M+UR8N:L<C9&VFOZ0EH;>BS;J@BXFFY?,1GE-40?0(MB(:[?I\*MNV&Q\BRUI
M79O6GH;?\ :G]Z6OCU"H/?;M%6W+$Y+-%WB1M&,+TV(SS7%B, 7AO-%.=MV%
M;/:!=GF+X]@[/)?&P'ON:NVP-W%*>)]D1RPN"?98ZZL9;:M%-<1S<<V]]6#/
MH9!;7[.^/^G]"?Z=3FAGXHPN:9%A&ERY?LTW.W]T=HKCO+<?:+L/%?VB-ELZ
M4;176_I/N#HD8;;Z!-)O-D@,L1QZ3\9->@$V0+*[3R=#4V+(%Q;:M/!SFFO>
M5)B^S4!_+NCNPZ:D1Q68JN6UDW^#-]+ODAK[GY,3<@IM57Y)+N/*WJ/KR52B
M=:/;%B<G&AS\ZN&3[\,SY4ZT<ANZY.ZF#_<^F?N^]_67Q1_P&1U&FLCXV0.R
MW2Z*3^CAG:]<20-X,;X?CRQ_T:\^IF<>>/R<A.O%R9Q5U9=TR#'F?$A_.# B
M#//G/C*;F(\Q,S(9-W$UKQ$+?U'-3I:Z%U7.RI=/0+20QS$.4K=GCY[C^*?3
M?J_(X@G10WMG3.&>J%P2^V7I<'AFQ<-6@Q]C+W^6>Y,O^&=\S^EDWZ.GV\:[
M)*=ZEAS0]//@3(\'%'\]\FBO&T)R7J-++K-&FLVS<Y%-*KM%.J7FTCA21A5;
M1:;IKNB';&TG%Z0<VB L_\8.\_V"[('N*#V/<U\D8Q .2# (H^?!,Q0=CV=A
M%<*F.RU>P%\A4VM%\[6VICR^21"_XKT#AC\CYG:D7L<K.!E=\BVCX]&QAR]>
M IV!&1D:M"E@9R1/A&T\URT&V)T#;&K$$/ZE,81E%#?!!!"/OMW _K/%VJW6
M%?)$M+/"SJ1'JLZF4ZLV*<DGT@]B9:@!3L8L[% <15JM9^?1+!5GYDEQ91HV
MI!:ZG3E20@;\%=:0_NT0%W$U[$Q<&>0?OQ'>A&:35 D+M=Z:^O@V^F/7(F3
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MV(V24T17VYZW?WJ=6=%M-%AF6/->F6T,<>;;<+Q;/81XW*[YQLZGBA>$]/4
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MN Q**)]5X9UGW8&JB27-*2\*RMZ41WSA>B$O+T4](>5!ZBE1&J8"D!U]'NM
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M__CVU;.G7_\_4$L! A0#%     @ 6($\5),*@TP] P  "@P  !$
M     ( !     &)C;&DM,C R,3$Q,34N>'-D4$L! A0#%     @ 6($\5/FN
M/4__"@  ;(<  !4              ( !; ,  &)C;&DM,C R,3$Q,35?;&%B
M+GAM;%!+ 0(4 Q0    ( %B!/%1&;+&?5P<  ,]8   5              "
M 9X.  !B8VQI+3(P,C$Q,3$U7W!R92YX;6Q02P$"% ,4    " !8@3Q4^VA[
M:PX3  !%:   $0              @ $H%@  =&TR,C,W,CED,5\X:RYH=&U0
M2P$"% ,4    " !8@3Q48L@I71D@  #=-@$ %0              @ %E*0
M=&TR,C,W,CED,5]E>#DY+3$N:'1M4$L! A0#%     @ 6($\5%;.\; H.@
M$R<! !4              ( !L4D  '1M,C(S-S(Y9#%?97@Y.2TR+FAT;5!+
4!08     !@ & (H!   ,A      !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
